Doron Therapeutics secures $11m to advance osteoarthritis drug
Longevity Technology - 29-Nov-2024Breakthrough MOTYS moves to phase 3 trials, promising lasting relief for knee osteoarthritis
Join the club for FREE to access the whole archive and other member benefits.
Breakthrough MOTYS moves to phase 3 trials, promising lasting relief for knee osteoarthritis
75% of participants experienced clinical improvement in both pain and function
Single dose injection targets root causes, offering long-term relief & improved quality of life
SIRT6 activation may be a potential therapeutic target for osteoarthritis
Liesel the gorilla is now walking again after receiving Stem CellX treatment
No resources found!
No blog posts found!